title: Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach.
abstract: OBJECTIVE
  To describe quadrivalent human papillomavirus (HPV) vaccination coverage achieved in the HPV vaccination catch-up program for girls aged 12-17 years.
  
  
  METHODS
  Analysis of data from the Australian National HPV Vaccination Program Register.
  
  
  METHODS
  Girls aged 12-17 years as at 30 June 2007.
  
  
  METHODS
  HPV vaccine coverage by dose (1, 2 and 3), age and state of residence, using Australian Bureau of Statistics estimates of resident populations as the denominator.
  
  
  RESULTS
  Notified vaccination coverage for girls aged 12-17 years nationally was 83% for dose 1, 78% for dose 2 and 70% for dose 3. The Australian Capital Territory and Victoria recorded the highest three-dose coverage for the 12-17-year-old cohort overall at 75%. The highest national three-dose coverage rate by age was achieved in 12-year-olds (74%). In Queensland, coverage among Indigenous girls compared with non-Indigenous girls was lower with each dose (lower by 4% for dose 1, 10% for dose 2 and 15% for dose 3). This pattern was not seen in the NT, where initial coverage was 17% lower among Indigenous girls, but the course completion rate among those who started vaccination was identical (84%).
  
  
  CONCLUSIONS
  The catch-up HPV vaccination program delivered over 1.9 million doses of HPV vaccine to girls aged 12-17 years, resulting in 70% of girls in this age group being fully vaccinated. The range in coverage achieved and the lower uptake documented among Indigenous girls suggest that HPV vaccination programs can be further improved.
authors.affiliation: National HPV Vaccination Program Register, Victorian Cytology Service, Melbourne, VIC, Australia. jbrother@vcs.org.au.
authors.forename: Julia M L
authors.initials: JM
authors.lastname: Brotherton
authors.forename: Sharron L
authors.initials: SL
authors.lastname: Murray
authors.forename: Madeline A
authors.initials: MA
authors.lastname: Hall
authors.forename: Lynne K
authors.initials: LK
authors.lastname: Andrewartha
authors.forename: Carolyn A
authors.initials: CA
authors.lastname: Banks
authors.forename: Dennis
authors.initials: D
authors.lastname: Meijer
authors.forename: Helen C
authors.initials: HC
authors.lastname: Pitcher
authors.forename: Megan M
authors.initials: MM
authors.lastname: Scully
authors.forename: Luda
authors.initials: L
authors.lastname: Molchanoff
mesh_terms: D000293:Adolescent; D001315:Australia / Q000453:epidemiology; D002648:Child; D005260:Female; D006801:Humans; D032541:Mass Vaccination / Q000379:methods / Q000458:organization & administration / Q000706:statistics & numerical data*; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D012042:Registries; D012572:School Health Services / Q000706:statistics & numerical data; D044465:White People / Q000706:statistics & numerical data
chemical_list: D053918:Papillomavirus Vaccines